Media
CEO Steven Lydeamore presents at The Capital Network's Emerging ASX Gems investment conference
4 November 2022
New investor guide profiles biotech companies to watch
27 September 2022
Immuron (ASX:IMC) shifts focus to therapeutic drug candidate
19 August 2022
Immuron (ASX:IMC) tables 494pc increase in North American FY22 Travelan sales
11 July 2022
Immuron (ASX:IMC) enters research agreement with Monash University
15 December 2020
Could Immuron’s (ASX:IMC) traveller’s diarrhoea treatment be used to fight COVID-19?
21 July 2020
Immuron reveals anti-COVID potential, raises $28 million
20 July 2020
Diarrhea: A major health issue for Americans travelling abroad
12 February 2020
Walter Reid Army Institute of Research 2019 Year in Review
15 January 2020
Immuron partnering with Walter Reid Army Institute of Research to test Travelan against Shigella, ETEC, Vibrio cholerae and Campylobacter jejuni isolates (2020, WRAIR's Investigator's Dispatch)
1 January 2020
Travelan on The Not Old Better Show with Dr. Hailey Weerts - Research Scientist of Walter Reed Army Institute of Research WRAIR
1 June 2019
Immuron CEO interviewed on the RedChip Money Report, USA
10 October 2018
No crap: Immuron is one step closer to an anti-gastro pill
16 July 2018
Big Pharma is watching as Immuron edges towards trial results
26 June 2018
Immuron reduces liver inflammation
2 March 2018
How Do You Recruit Patients Unaware Of Their Disease?
1 March 2018
Immuron's fatty liver disease candidate advancing — 4 insights
14 September 2017
In dash to NASH, Immuron targets the gut not the liver
28 March 2017
Biotech tackles hospital infection
17 March 2017